Clioxanide

Clioxanide

SCHEMBL636665

CC(=O)Oc1c(I)cc(I)cc1C(=O)Nc1ccc(Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 1.00
NLRP3 Q96P20 1/20 1.00
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
HTT P42858 2/20 0.50
HSPD1 P10809 1/20 0.50
PNLIP P16233 1/20 0.50
PIK3CA P42336 1/20 0.50
BLM P54132 1/20 0.50
HSPE1 P61604 1/20 0.50
TOP1 P11387 1/20 0.47
P2RX1 P51575 1/20 0.46
ALDH1A1 P00352 2/20 0.45
NR1H4 Q96RI1 1/20 0.44
HDAC8 Q9BY41 3/20 0.43
HDAC1 Q13547 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
F10 P00742 1/20 0.42
NPC1 O15118 2/20 0.41
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clioxanide SCHEMBL29358452 1.00 POLB (1.00) POLBNLRP3KMT2AMEN1HTT
SCHEMBL20413309 0.88 POLB (0.79) POLBNLRP3KMT2AMEN1HTT
SCHEMBL26176577 0.86 POLB (0.76) POLBNLRP3KMT2AMEN1HTT
Clioxanide SCHEMBL5307331 0.86 POLB (0.74) POLBNLRP3KMT2AMEN1HTT
SCHEMBL14223805 0.84 POLB (0.72) POLBNLRP3KMT2AMEN1HTT
SCHEMBL14195181 0.81 POLB (0.68) POLBNLRP3TOP1ALDH1A1NR1H4
SCHEMBL14223829 0.81 POLB (0.67) POLBNLRP3KMT2AMEN1HTT
SCHEMBL20413314 0.80 POLB (0.67) POLBNLRP3KMT2AMEN1TOP1
SCHEMBL14195174 0.78 KMT2A (0.70) POLBNLRP3KMT2AMEN1HTT
SCHEMBL23095652 0.78 POLB (0.64) POLBNLRP3KMT2AMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091043-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS DATA2DISCOVERY INC (US) 2026-04-02 US claimed
EP-4586826-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL In the Bowl Animal Health, Inc. (US) 2025-07-23 EP claimed
WO-2024064209-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS DATA2DISCOVERY, INC. (US) 2024-03-28 WO claimed
WO-2024059837-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL IN THE BOWL ANIMAL HEALTH, INC. (US) 2024-03-21 WO claimed
US-11166926-B2 Compositions and methods for protecting a host from enteric toxigenic pathogens THE HOSPITAL FOR SICK CHILDREN (CA) 2021-11-09 US claimed
US-20210137948-A1 TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE UNION therapeutics A/S (DK) 2021-05-13 US claimed
EP-3773602-A1 TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE UNION therapeutics A/S (DK) 2021-02-17 EP claimed
US-20200046659-A1 COMPOSITIONS AND METHODS FOR PROTECTING A HOST FROM ENTERIC TOXIGENIC PATHOGENS UNIVERSITY OF MARYLAND, BALTIMORE 2020-02-13 US claimed
US-10463680-B2 Halogenated salicylanilides for treating clostridium infections UNION therapeutics A/S (DK) 2019-11-05 US claimed
WO-2019192968-A1 TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE UNION therapeutics A/S (DK) 2019-10-10 WO claimed
WO-2004006906-A2 METHODS FOR THE TREATMENT OF NEOPLASMS COMBINATORX, INCORPORATED (US) 2004-01-22 WO claimed
CN-1386507-A Compound antiparasitic medicine for fish or full-value feed containing antiparasitic medicine WANG YUWAN (CN) 2002-12-25 CN claimed
EP-0710105-A4 SYNERGISTIC ANTHELMINTIC COMPOSITIONS UNIV AUSTRALIAN (AU) 1998-06-10 EP claimed
EP-0710105-A1 SYNERGISTIC ANTHELMINTIC COMPOSITIONS THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 1996-05-08 EP claimed
WO-1994028887-A1 SYNERGISTIC ANTHELMINTIC COMPOSITIONS THE AUSTRALIAN NATIONAL UNIVERSITY (AU) 1994-12-22 WO claimed
US-4957494-A Multi-layer delivery system ALZA CORPORATION (US) 1990-09-18 US claimed
US-4874388-A Multi-layer delivery system ALZA CORPORATION (US) 1989-10-17 US claimed
EP-0059074-B1 ANTHELMINTIC COMPOSITION AND THE USE THEREOF SANKYO COMPANY LIMITED (JP) 1984-10-10 EP claimed
US-4468390-A Anthelmintic composition and the use thereof SANKYO COMPANY, LIMITED (JP) 1984-08-28 US claimed
EP-0059074-A1 Anthelmintic composition and the use thereof SANKYO COMPANY LIMITED (JP) 1982-09-01 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10463680-B2 Halogenated salicylanilides for treating clostridium infections SLC10A2, FABP2, SI POLB 3243/4885NLRP3 810/4885KMT2A 2484/4885
US-20260091043-A1 COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIUM INFECTIONS AHCY, MACO1, ME3 POLB 1888/4885NLRP3 83/4885KMT2A 3975/4885
US-20210137948-A1 TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE MGLL, NIT2, SI POLB 1391/4885NLRP3 2299/4885KMT2A 4069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.